NASDAQ OMX

Immunicum AB (publ) Presents Case Study of One Patient from Phase I/II HCC Trial at Cholangiocarcinoma Foundation Annual Conference

Dela

Press Release

5 February 2018

Immunicum AB (publ) Presents Case Study of One Patient from Phase I/II HCC Trial at Cholangiocarcinoma Foundation Annual Conference

Immunicum AB (publ; IMMU.ST) a biopharmaceutical company advancing a novel, immune-priming cancer treatment against a variety of solid tumors, announced today the presentation of a case study on an individual patient included in the Phase I/II Hepatocellular Carcinoma (HCC) trial at the poster session held during the Cholangiocarcinoma Foundation Annual Conference in Salt Lake City, Utah. The case study highlighted the long survival of one patient with advanced cholangiocarcinoma (bile duct cancer) after combination of the immune primer ilixadencel with standard drugs known to induce immunogenic cell death and inhibit tumor-driven immunosuppression.

"The information from this case study further supports and complements the positive overall safety and immune response data from the Phase I/II HCC clinical study that we announced in September 2017," said Peter Suenaert, Chief Medical Officer at Immunicum. "We value being selected by the Cholangiocarcinoma Foundation to present this one patient's positive response to ilixadencel treatment when combined with certain standard drugs. Presentations at conferences such as this one provide us with a chance to interact with the medical and scientific community focused on treating this rare form of cancer."

In the study, the bile duct cancer patient first received a transarterial chemo-embolization (TACE), which is a standard method to deliver a chemotherapeutic drug directly to the tumor while also restricting blood supply to the tumor. The drug used for this patient was doxorubicin which is known to induce a local immunogenic cell death. The TACE treatment was repeated two times. Ilixadencel, which is aimed to locally recruit and activate endogenous dendritic cells, was administered intratumorally the day after each TACE treatment for a total of three treatments. The tumor did not progress until month 6 at which point the patient received a systemic chemotherapy regimen consisting of gemcitabine + cisplatin, that is believed to lift the immunosuppression in the tumor. The survival of the patient was 41 months, which is positive when compared to historical data. This case study is one example that supports the thesis that treatment with ilixadencel may provide clinical benefit in this form of cancer.

The poster titled, "Combination treatment of immune primer ilixadencel with standard therapy known to inhibit immunosuppression: a case report," was presented at the Cholangiocarcinoma Foundation Annual Conference on February 1, 2018. The poster can be found on Immunicum's website under "Publications" or by accessing the following link: http://immunicum.se/technology/publications/

About Cholangiocarcinoma
Cholangiocarcinoma, or bile duct cancer, arises from the epithelial cells lining the intra- and extrahepatic bile ducts. Intrahepatic cholangiocarcinoma is estimated to account for approximatively 15% of the incidence of primary liver cancers in the US. This tumor type is difficult to diagnose accurately and/or early, so by the time of diagnosis it is often too advanced for surgery, which is currently the only potential curative treatment.

About Cholangiocarcinoma Foundation Annual Conference
The Cholangiocarcinoma Foundation's annual program seeks to develop sustainable participation of the medical and research communities in the field of cholangiocarcinoma by providing a forum to increase knowledge central to the prevention, diagnosis, treatment, and cure for cholangiocarcinoma; presenting a diversity of perspectives focused on clinical, basic, and translational research; stimulating multi-disciplinary, cross-institutional collaborations; and fostering dialogue and inspiring innovation.

About ilixadencel
Ilixadencel, a cell therapy product (formerly known as INTUVAX®), is an off-the-shelf cancer immune primer, developed for the treatment of solid tumors. Its active ingredient is activated allogeneic dendritic cells, derived from healthy blood donors. Intratumoral injection of these cells generates an inflammatory response which in turn leads to tumor-specific activation of the patient's cytotoxic T-cells.

For more information, please contact:

Carlos de Sousa, CEO, Immunicum
Telephone: +46 (0) 31 41 50 52
E-mail: info@immunicum.com  

INVESTOR RELATIONS

Michaela Gertz, CFO, Immunicum
Telephone: +46 70 926 17 75
E-mail: ir@immunicum.com 

Media Relations EU/US

Gretchen Schweitzer and Joanne Tudorica
Trophic Communications
Telephone: +49 172 861 8540
E-mail: ir@immunicum.com 

About Immunicum AB (publ)

Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient's own immune system to fight cancer. The company's lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq Stockholm. www.immunicum.com

 



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Immunicum AB via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Inspiration Mining to File a Complaint with OSC Against Stockwatch20.2.2018 21:35Pressmeddelande

TORONTO, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Inspiration Mining Corporation (the Corporation) (CSE:ISM) reports that Stockwatch, a Vancouver based news service, has published incorrect news. Inspiration intends to initiate a one (1) for two (2) FORWARD SPLIT. Inspiration fully intends to bring forth a resolution at its upcoming Annual General Meeting to initiate a FORWARD SPLIT, on a one (1) old share for two (2) new share basis. For further information, please contact Randy Miller, Chief Executive Officer of the Corporation, at tel: 416-842-9000, www.inspirationmining.com. The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This press release contains forward-looking statements based on assumptions, uncertainties and management's best estimates of future events. Actual results may differ materially from those currently anticipated. Investors are cautioned that such forward-looking statements involve risks and uncertainties. Important

Aurora Releases Third Quarter Results20.2.2018 21:08Pressmeddelande

Aurora Solar Technologies Inc. / Aurora Releases Third Quarter Results . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. NORTH VANCOUVER, British Columbia, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Aurora Solar Technologies Inc. ("Aurora")("Company") (TSX.V:ACU) (OTCBB:AACTF) (FSE:A82), a leader in inline measurement and control technology for the photovoltaic manufacturing industry, released today its third quarter results. Revenue for the quarter was $337,325, gross margin was 62.9%, resulting in an operating income loss of ($398,959). Year-to-date for nine months, the Company has recognized $1,903,020 in revenue, an increase of 238% over the same period last year. The operating income (loss) year to date was ($674,983), a reduction of 67.7% from the same period last fiscal year. The Company also confirms, excluding new potential orders, that it has unrecognized revenue from shipments and order backlog of approxi

Bermuda Principles event merges science and business20.2.2018 16:36Pressmeddelande

HAMILTON, Bermuda, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Scientists and researchers from around the world are gathering in Bermuda this week for the second edition of a conference exploring the field of genetic research. Premier the Hon David Burt will officially open "Bermuda Principles: Impact on Splicing" Wednesday evening at the Fairmont Southampton. The conference, which runs through Saturday, has registered 50 delegates, along with an impressive roster of 36 speakers and panellists from 11 countries, including Australia, Denmark, Switzerland and South Africa. Among the attendees are prominent geneticists, scientists, professors, researchers, PhD students working in international labs, biotech representatives and investors. "I am elated to see the growth of the conference since last year's event," said Bermudian Dr. Carika Weldon, a biomedical researcher with her own lab at De Montfort University, UK, who conceived of the event and launched it last February. "My main aim has been to p

Globecomm Joins Amazon Web Services Partner Network20.2.2018 16:00Pressmeddelande

Highlights Globecomm establishes direct access to Amazon Web Services (AWS) Direct Connect at key datacenter locations. Customers in U.S. Government, media and entertainment, enterprise video and the Internet of Things (IoT) can interoperate cloud-based services with Globecomm's global satellite and fiber network to reduce capital expenditure and ramp up networks and services faster. Globecomm's suite of Software-as-a-Service (SaaS) applications run on AWS, accessible across both AWS and Globecomm's global network. Globecomm's team in place to design, develop and deliver cloud-centric as well as hybrid architectures for end-to-end services and customer solutions. HAUPPAUGE, N.Y., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Globecomm announced today that it has joined the Amazon Web Services (AWS) Partner Network (APN) as a Standard Technology Partner. This agreement will enable Globecomm to seamlessly interoperate its global satellite and fiber network with AWS's storage, compute and cloud conte

Elite Capital & Co. awarded Infrastructure Project Finance Provider 2018 by New European Economy20.2.2018 15:41Pressmeddelande

LONDON, Feb. 20, 2018 (GLOBE NEWSWIRE) -- The Information Department at Elite Capital & Co. Limited (ECC), announced today that the company features in the specialized and prestigious New European Economy Magazine in its January 2018 issue in Britain and the European Union countries as the "Infrastructure Project Finance Provider 2018". The award is the result of focused efforts and synergy between the ECC Board of Directors and our employees and strategic partners all over the world over the past years. It also reflects the ability of the Company's strategy to adapt to the prevailing global economic circumstances and testifies to the viability of the planning process adopted by the Board of Directors. Dr. Faisal Khazaal, Chairman of Elite Capital & Co. commented on the occasion, "I should thank Mr. George Matharu, President of ECC and his Board Members who make ceaseless efforts towards ensuring that ECC continues to occupy a prestigious position in the field of finance and economy in

New MindManager 11 for Mac: Visually Capture, Organize, and Share Information to Drive Project and Business Success20.2.2018 15:26Pressmeddelande

Powerful mind mapping and information visualization software introduces its most robust Mac version yet; complete with new diagram types, an expanded template library, advanced mapping capabilities, and improved sharing options OTTAWA, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Introduced today, MindManager® 11 for Mac brings new elegance and efficiency to the way individuals and teams organize ideas, tackle tasks, and achieve their goals. Already a leader in mind mapping and information visualization on the Mac, MindManager's new release offers advanced mapping capabilities, new diagram types and templates, and easy ways to share and publish your work - all delivered within a redesigned interface optimized to enhance productivity. Individuals, small businesses, and global organizations rely upon MindManager to efficiently brainstorm and organize ideas, communicate knowledge effectively, and execute project success. MindManager enables users to turn unstructured ideas and information into dynam

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum